Skip to content

PP&E (Net) at other companies

Pfizer logo
PfizerPFE
$19.4B+5.8%
Merck & Co. logo
Merck & Co.MRK
$25.43B+2.6%
Moderna logo
ModernaMRNA
$2.09B-5.7%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$153.58M+1.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$112.79M-16.6%

Segments

By geography

See full
SWITZERLAND$219.4M+24.2%
UNITED STATES$41.3M+2.0%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s PP&E (net)?
Vaxcyte, Inc. (PCVX) reported PP&E (net) of $260.7M in Q1 2026.
How has Vaxcyte, Inc.'s PP&E (net) changed year-over-year?
Vaxcyte, Inc.'s PP&E (net) increased by 20.1% year-over-year, from $217.16M to $260.7M.
What is the long-term trend for Vaxcyte, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s PP&E (net) has grown at a 139.4% compound annual growth rate (CAGR), from $3.27M to $257.37M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.